A. THOMAS ANDREWS, M.D.; HERBERT S. BOWMAN, M.D.; SHASHIKANT B. PATEL, M.D.; WILLIAM M. ANDERSON, M.D.
To the editor: Orwoll and others (1) have reported in the September issue on the association of mitomycin with interstitial pneumonia. In the past 2 years we have seen two patients who died with unexplained severe interstitial pneumonitis after receiving mitomycin chemotherapy.
The first case was that of a 53-year-old man with adenocarcinoma of the pancreas who received weekly mitomycin, 5-fluorouracil, and cytosine arabinoside during an 18-week period for a total mitomycin dose of 50 mg. He developed progressive dyspnea leading to death within 3 weeks after a short preterminal period of progressive dyspnea. At autopsy, alveolar septal thickening and
A. THOMAS ANDREWS, HERBERT S. BOWMAN, SHASHIKANT B. PATEL, WILLIAM M. ANDERSON. Mitomycin and Interstitial Pneumonitis. Ann Intern Med. 1979;90:127. doi: 10.7326/0003-4819-90-1-127_1
Download citation file:
Published: Ann Intern Med. 1979;90(1):127.
Copyright © 2017 American College of Physicians. All Rights Reserved.
Print ISSN: 0003-4819 | Online ISSN: 1539-3704
Conditions of Use